ReviewDiagnostics (Basel, Switzerland)2026
Emerging Endorobotic and AI Technologies in Colorectal Cancer Screening: A Review of Design, Validation, and Translational Pathways.
Review in Diagnostics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advances in artificial intelligence (AI), soft robotics, and miniaturized imaging technologies have accelerated the development of endorobotic platforms that aim to enhance detection accuracy and improve patient experience. In this narrative review, we synthesize evidence on AI-assisted detection and characterization systems (CADe/CADx), robotic locomotion mechanisms, adhesion strategies, imaging modalities, and material and power constraints relating to next-generation CRC screening technologies. Reported performance metrics are interpreted within their original methodological contexts, acknowledging the heterogeneity of datasets, limited representation of diverse populations, underreporting of negative findings, and scarcity of large, real-world comparative trials. We introduce a conceptual translational framework that links engineering design principles with validation needs across in silico, in vitro, preclinical, and clinical stages, and we outline safety considerations, workflow integration challenges, and sterility requirements that influence real-world deployability. Regulatory alignment is discussed using the U.S. FDA Total Product Life Cycle (TPLC) and Good Machine Learning Practice (GMLP) frameworks to highlight expectations for data quality, model robustness, device-software interoperability, and post-market monitoring. Collectively, the evidence demonstrates promising technological innovation but also highlights substantial gaps that must be addressed before AI-enabled endorobotic systems can be safely and effectively integrated into routine CRC screening. Continued interdisciplinary work, supported by rigorous validation and transparent reporting, will be essential to advance these technologies toward meaningful clinical impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.